Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
capecitabine (xeloda) (1 trial)
fulvestrant (faslodex) (1 trial)
sorafenib (nexavar) (1 trial)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Trials (2 total)
Trial APIs (3 total)